Closed Linear DNA Production for High-Fidelity Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene delivery systems, such as plasmid DNA vectors, face challenges including adverse immune responses, low transfection efficiency, and the need for high production yields, while existing methods for producing closed linear DNA (clDNA) are inadequate for large-scale, safe, and cost-effective production with high sequence fidelity.
Innovation Solution
A process using a primase/polymerase enzyme for priming DNA amplification followed by rolling-circle amplification to produce clDNA, which is then purified, ensuring high sequence fidelity and scalability without the use of microorganisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional plasmid DNA vectors are used for gene therapy, then gene delivery can be achieved, but adverse immune responses occur due to bacterial sequences and bioavailability is compromised due to large molecular size
Solution Approach 1:
The invention extracts and removes the bacterial backbone sequences from plasmid DNA vectors, retaining only the essential gene delivery components. This is achieved through enzymatic digestion with restriction enzymes that cleave bacterial DNA sequences, leaving purified eukaryotic expression cassettes that lack immunogenic elements while maintaining gene delivery functionality.
Solution Approach 2:
The plasmid DNA vector is segmented into distinct functional components: bacterial backbone sequences (removed) and eukaryotic expression cassette (retained). The expression cassette is further segmented into promoter, gene of interest, and terminator regions, allowing selective purification of the therapeutic components while discarding harmful bacterial elements.
2Reliability
If non-viral vectors are used instead of viral vectors, then safety is improved and transgene capacity is increased, but transfection efficiency becomes very limited
Solution Approach 1:
The invention changes the physical and chemical parameters of the DNA vector by removing supercoiling and circular structure, producing linearized DNA fragments with defined ends. This structural parameter change improves cellular uptake efficiency while maintaining the safety advantages of non-viral vectors and the high transgene capacity of plasmid-based systems.
3Productivity
If clDNA vectors are produced using existing methods, then some production yield is achieved, but bacterial components and antibiotic resistance sequences remain contaminating the product
Solution Approach 1:
The invention implements a continuous purification process where enzymatic digestion, gel electrophoresis separation, and elution steps are performed in sequence without interrupting the flow of DNA material. This continuous action ensures complete removal of bacterial contaminants while maintaining high recovery of the desired clDNA product, achieving both high yield and high purity.
Solution Approach 2:
The invention uses gel electrophoresis as an intermediary separation mechanism that physically divides bacterial DNA fragments from eukaryotic expression cassettes based on size and charge differences. The gel matrix acts as a mediator that allows selective passage and retention of different DNA species, enabling clean separation without direct chemical interaction that might damage the therapeutic DNA.
4Productivity
If large-scale production of clDNA is attempted with existing processes, then production volume increases, but costs increase and sequence homogeneity decreases
Solution Approach 1:
The invention uses a template-based amplification approach where a single high-quality parent plasmid serves as a template for generating multiple identical clDNA copies through controlled enzymatic reactions. This copying mechanism ensures that all produced molecules are exact replicas of the validated template sequence, maintaining high sequence homogeneity even at large production scales while reducing costs by eliminating the need for individual sequencing verification of each batch.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high-yield, high-fidelity clDNA production suitable for therapeutic use, with improved transfection efficiency and reduced risks, allowing for efficient gene expression in mammalian cells.
Implementation Method 1
a primase/polymerase for priming the amplification of a template DNA
Implementation Method 2
followed by rolling-circle amplification to produce clDNA
Data Source
AI summary
The present invention provides a process for the production of a closed linear DNA comprising the steps of (a) providing a DNA template comprising a DNA sequence of interest; (b) amplifying DNA from the DNA template of step (a) wherein the amplification is primed with a primase/polymerase enzyme; (c) generating a closed linear DNA with the amplified DNA produced in step (b); and (d) purifying the closed linear DNA produced in step (c). The invention also provides a closed linear DNA obtainable according to the process of the invention, a pharmaceutical composition comprising a therapeutically effective amount of the closed linear DNA of the invention, and a concatameric DNA comprising repeats of a DNA sequence of interest.